The FDA on May 13, 2026, granted accelerated approval to BEQALZI®, a BCL-2 inhibitor, for adults with relapsed or refractory Mantle Cell Lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s Tyrosine Kinase (BTK) inhibitor. BEQALZI® is a product of BeOne Medicines USA, Inc.
Bottom Ad
Advertisement
Subscribe
